中老年和老年患者的生存预测与伯基特淋巴瘤:基于SEER数据的综合性诺摩图谱方法
Xia Cao1, Duanzong Zhang1, Jichang Gong1
1Department of Hematology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Cancer medicine
|November 10, 2025
概括
这项研究开发了一种名谱,用于预测中年和老年伯基特淋巴瘤 (BL) 患者的生存率. 该工具有助于针对这个特定人群进行个性化风险分层和治疗管理.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 生物统计学 生物统计学
背景情况:
- 老年人的伯基特淋巴瘤 (BL) 呈现出独特的预后挑战.
- 现有的预后工具不能充分解决这个队列中的特定年龄生存率.
研究的目的:
- 为中年和老年BL患者开发个性化的生存预测工具.
- 在这个人群中确定总生存 (OS) 和癌症特异性生存 (CSS) 的独立预后因素.
主要方法:
- 利用了45岁以上患者的监测,流行病学和最终结果 (SEER) 数据 (2000-2020年).
- 进行单变量和多变量考克斯回归分析.
- 构建并验证了用于OS和CSS预测的nomograms.
主要成果:
- 确定了年龄,种族,安纳堡阶段和化疗作为OS的独立预测因素.
- 确定了年龄,安纳伯阶段,放射治疗,化疗和瘤质量作为CSS的独立预测因素.
- 诺莫格拉姆证明了对1年,3年和5年的OS和CSS概率的准确预测.
结论:
- 开发的名图表可以作为个性化工具来预测BL患者的生存率.
- 该模型有助于区分不同风险组的生存概率.
- 为老年BL患者的风险分层和治疗策略提供了宝贵的见解.
更多相关视频
相关概念视频
Cancer Survival Analysis
634
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
634
Kaplan-Meier Approach
547
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
547
Actuarial Approach
281
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
281
Comparing the Survival Analysis of Two or More Groups
542
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
542
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
226
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
226
Life Tables
485
A life table is a statistical tool that summarizes the mortality and survival patterns of a population, providing detailed insights into the likelihood of survival or death across different age intervals within a cohort. By organizing data on survival probabilities and mortality rates, life tables offer a clear snapshot of population dynamics over time. They are extensively used in demography, public health, actuarial science, and ecology to analyze life expectancy, design health interventions,...
485


